Replies to post #11 on Syndax Pharmaceuticals Inc (SNDX)

[tika1]

Dew,

SNDX could be multi-bagger if they can show good Phase III result in Entinostat with other combination.

They also have FDA breakthrough designation which is huge stamp of appreciation from FDA. If drug's indication is cancer and it has BTD status chance of approval is more than 70%.

I have one question though, what is potential peak revenue for Entinostat, if they manage to get FDA approval.